Benzinga.com

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

The OLE study involves 330 participants who completed the 30-month ATTRibute-CM Phase 3 study. Key initial results from the OLE study show that continuous treatment with acoramidis led to: The OLE ...
The American Journal of Managed Care

Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...
Seeking Alpha

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysis This ...
Healio

Acoramidis approved to reduce CV death, hospitalization for cardiac amyloidosis

Please provide your email address to receive an email when new articles are posted on . Acoramidis received FDA approval for reduction of CV death and hospitalization in patients with amyloid ...
Nasdaq

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) ...
The American Journal of Managed Care

Key Efficacy and Safety Considerations for Payers in ATTR-CM

Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety. This episode, titled ‘Key Efficacy and Safety ...
Seeking Alpha

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk reduction in ACM/ first CVH ...
FOX8 Cleveland

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society ...

- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment across key ...
TCTMD

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

MINNEAPOLIS, MN—Treatment with acoramidis (Attruby; BridgeBio Pharma) compared with placebo appears to reduce cumulative cardiovascular events by almost half among patients who have transthyretin ...
MedPage Today

Acoramidis Snags FDA Approval for ATTR Cardiomyopathy

Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced. Offering patients near-complete TTR ...
ksn.com

BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

- Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8 (p<0.0001) - 58% of ties in Finkelstein-Schoenfeld (F-S) primary analysis broken by all-cause mortality ...